CA3011363A1 - Methods for predicting response to treatment - Google Patents

Methods for predicting response to treatment Download PDF

Info

Publication number
CA3011363A1
CA3011363A1 CA3011363A CA3011363A CA3011363A1 CA 3011363 A1 CA3011363 A1 CA 3011363A1 CA 3011363 A CA3011363 A CA 3011363A CA 3011363 A CA3011363 A CA 3011363A CA 3011363 A1 CA3011363 A1 CA 3011363A1
Authority
CA
Canada
Prior art keywords
composite
human subject
genetic pattern
polymorphic locus
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011363A
Other languages
English (en)
French (fr)
Inventor
Lynn Doucette-Stamm
Gordon W. Duff
Kenneth S. Kornman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of CA3011363A1 publication Critical patent/CA3011363A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA3011363A 2016-01-12 2017-01-12 Methods for predicting response to treatment Pending CA3011363A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277760P 2016-01-12 2016-01-12
US62/277,760 2016-01-12
PCT/US2017/013101 WO2017123696A1 (en) 2016-01-12 2017-01-12 Methods for predicting response to treatment

Publications (1)

Publication Number Publication Date
CA3011363A1 true CA3011363A1 (en) 2017-07-20

Family

ID=57956384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011363A Pending CA3011363A1 (en) 2016-01-12 2017-01-12 Methods for predicting response to treatment

Country Status (6)

Country Link
US (2) US10894985B2 (enExample)
EP (1) EP3402900A1 (enExample)
JP (1) JP2019503176A (enExample)
AU (1) AU2017207341A1 (enExample)
CA (1) CA3011363A1 (enExample)
WO (1) WO2017123696A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
DE102018104133B4 (de) * 2018-02-23 2025-02-20 Klinikum der Universität München, Anstalt des öffentlichen Rechts Biomarker zur Feststellung einer möglichen Unverträglichkeit gegenüber Metallimplantaten
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
JP7108574B2 (ja) * 2019-04-23 2022-07-28 ジェネシスヘルスケア株式会社 アレルギー性結膜炎のリスクを判定する方法
CA3142662A1 (en) * 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) * 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
ATE173508T1 (de) 1988-05-20 1998-12-15 Hoffmann La Roche Befestigung von sequenzspezifischen proben
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
JP2001507921A (ja) 1992-04-27 2001-06-19 トラスティーズ オブ ダートマス カレッジ 生物学的液体中の遺伝子配列の検出
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US6027923A (en) 1993-07-23 2000-02-22 Bio-Rad Laboratories, Inc. Linked linear amplification of nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5657255C1 (en) 1995-04-14 2002-06-11 Interleukin Genetics Inc Hierarchic biological modelling system and method
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
EP2332957B1 (en) 1996-02-09 2015-04-08 Cornell Research Foundation, Inc. Detection of nucleic and acid sequence differences using the ligase detection reaction with addressable arrays
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6108635A (en) 1996-05-22 2000-08-22 Interleukin Genetics, Inc. Integrated disease information system
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2003500005A (ja) 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
IL147182A0 (en) 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
MXPA02002251A (es) 1999-08-30 2003-08-20 Interleukin Genetics Inc Diagnosticos y terapeuticos para osteoporosis.
US20100255475A1 (en) 1999-08-30 2010-10-07 Kornman Kenneth S Diagnostics and therapeutics for osteoporosis
US20090023147A1 (en) 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US20060183161A1 (en) 2000-07-17 2006-08-17 Martin Nicklin IL-ILI gene and polypeptide products
EP1373504A2 (en) 2001-01-08 2004-01-02 Interleukin Genetics, Inc. Mammalian tribbles signaling pathways and methods and reagents related thereto
EP1407005A4 (en) 2001-06-11 2006-05-31 Interleukin Genetics Inc INTEGRATIVE TESTING TECHNIQUES FOR CONTROLLING MOLECULAR ASSEMBLY EVENTS
EP1409737A4 (en) 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
CN1753903B (zh) 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
US20080311581A1 (en) 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
JP2007501627A (ja) 2003-08-08 2007-02-01 インタールーキン ジェネティックス インク 骨粗鬆症のための診断法および治療法
US20080118920A1 (en) 2004-05-03 2008-05-22 Duff Gordon W Diagnostics And Therapeutics For Diseases Associated With An Il-1 Inflammatory Haplotype
US20060252050A1 (en) 2005-05-06 2006-11-09 Ordovas Jose M Genetic marker for weight regulation
US8105775B2 (en) 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU2007249801A1 (en) 2006-05-12 2007-11-22 Interleukin Genetics, Inc. Food compositions and methods of treating periodontal disease
ES2431671T3 (es) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
JP2011502510A (ja) 2007-11-08 2011-01-27 インタールーキン ジェネティクス， インコーポレイテッド 老化に関係がある皮膚疾患の診断
EP2283156B1 (en) 2008-05-02 2015-11-11 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
WO2009135219A2 (en) 2008-05-02 2009-11-05 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20100136561A1 (en) 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
NZ589863A (en) 2008-05-16 2012-11-30 Interleukin Genetics Inc Genetic markers for weight management and methods of use thereof
CA2731028A1 (en) 2008-07-18 2010-01-21 Interleukin Genetics, Inc. Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases
US20100112570A1 (en) 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
WO2011006070A2 (en) 2009-07-09 2011-01-13 Interleukin Genetics, Inc. Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss
US20120208187A1 (en) 2010-12-09 2012-08-16 Kenneth Kornman Method and Kit for Determining Severity and Progression of Periodontal Disease
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease

Also Published As

Publication number Publication date
JP2019503176A (ja) 2019-02-07
EP3402900A1 (en) 2018-11-21
US10894985B2 (en) 2021-01-19
AU2017207341A1 (en) 2018-08-02
WO2017123696A1 (en) 2017-07-20
US20170198350A1 (en) 2017-07-13
US20210164052A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US20210164052A1 (en) Methods for predicting response to treatment
US20230100271A1 (en) Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US11486006B2 (en) Methods and kits for treating cardiovascular disease
JP2022033877A (ja) スタチンの応答および心血管疾患に関連する遺伝子多型、その検出方法ならびに使用
JP2017201989A (ja) 脳卒中に関連した遺伝子遺伝子多型およびその検出方法および使用
JP6496003B2 (ja) Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー
JP6272860B2 (ja) 軟骨障害の予後バイオマーカー
US20180105877A1 (en) Genetic polymorphisms associated with depression
WO2021205013A1 (en) Compositions and methods for treating covid-19
US20060240450A1 (en) Genetic analysis for stratification of cancer risk
WO2021028469A1 (en) Compositions and methods for treating cytokine release syndrome and neurotoxicity
US20220333169A1 (en) Polygenic Score for Cardiac Heart Failure
US9670545B2 (en) Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function
US20070289889A1 (en) Biomarkers For The Prediction Of Drug-In Duced Diarrhea
US20060178843A1 (en) Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
US20060183146A1 (en) Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs
US9873920B2 (en) Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting MUC4 gene polymorphism
US20160051527A1 (en) Methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220111